Chronic lymphocytic leukemia with del13q14 as the sole abnormality: Dynamic prognostic estimate by interphase-FISH

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This study analyzed 140 patients with isolated del13q14 on interphase FISH (I-FISH), to identify subsets with a different progression risk and to assess the acquisition of additional chromosomal abnormalities (clonal evolution) in treatment-naïve del13q14 patients. A monoallelic deletion (del13qx1) was detected in 123 cases (88%), a biallelic deletion (del13qx2) in eight and a mosaic of monoallelic and biallelic deletions (del13qx1/del13qx2) in nine. In 33% of cases, deletion encompassed the Rb1 locus The median percentage of abnormal nuclei was 50% (15%-96%), and it was higher in patients with a biallelic/mosaic pattern in comparison with patients with monoallelic deletion. Sixty two patients (44%) have been treated; 5-year treatment free survival rate was 56% and the median treatment free survival was 65months. The baseline percentage of deleted nuclei, as a continuous variable, was related to progression (HR: 1.02; p=0.001). According to deletion burden, three groups were identified: 64 cases (46%) had

Original languageEnglish
Pages (from-to)136-142
Number of pages7
JournalHematological Oncology
Volume31
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Interphase
B-Cell Chronic Lymphocytic Leukemia
Clonal Evolution
Chromosome Aberrations
Therapeutics
Survival Rate
Survival

Keywords

  • Chronic lymphocytic leukemia
  • Del13q14
  • Interphase-FISH
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{f62ea2dae3fd4bd0a63113e1cfd890c1,
title = "Chronic lymphocytic leukemia with del13q14 as the sole abnormality: Dynamic prognostic estimate by interphase-FISH",
abstract = "This study analyzed 140 patients with isolated del13q14 on interphase FISH (I-FISH), to identify subsets with a different progression risk and to assess the acquisition of additional chromosomal abnormalities (clonal evolution) in treatment-na{\"i}ve del13q14 patients. A monoallelic deletion (del13qx1) was detected in 123 cases (88{\%}), a biallelic deletion (del13qx2) in eight and a mosaic of monoallelic and biallelic deletions (del13qx1/del13qx2) in nine. In 33{\%} of cases, deletion encompassed the Rb1 locus The median percentage of abnormal nuclei was 50{\%} (15{\%}-96{\%}), and it was higher in patients with a biallelic/mosaic pattern in comparison with patients with monoallelic deletion. Sixty two patients (44{\%}) have been treated; 5-year treatment free survival rate was 56{\%} and the median treatment free survival was 65months. The baseline percentage of deleted nuclei, as a continuous variable, was related to progression (HR: 1.02; p=0.001). According to deletion burden, three groups were identified: 64 cases (46{\%}) had",
keywords = "Chronic lymphocytic leukemia, Del13q14, Interphase-FISH, Prognosis",
author = "Orlandi, {Ester M.} and Paolo Bernasconi and Cristiana Pascutto and Ilaria Giardini and Cavigliano, {Paola M.} and Marina Boni and Silvia Zibellini and Mario Cazzola",
year = "2013",
month = "9",
doi = "10.1002/hon.2032",
language = "English",
volume = "31",
pages = "136--142",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "3",

}

TY - JOUR

T1 - Chronic lymphocytic leukemia with del13q14 as the sole abnormality

T2 - Dynamic prognostic estimate by interphase-FISH

AU - Orlandi, Ester M.

AU - Bernasconi, Paolo

AU - Pascutto, Cristiana

AU - Giardini, Ilaria

AU - Cavigliano, Paola M.

AU - Boni, Marina

AU - Zibellini, Silvia

AU - Cazzola, Mario

PY - 2013/9

Y1 - 2013/9

N2 - This study analyzed 140 patients with isolated del13q14 on interphase FISH (I-FISH), to identify subsets with a different progression risk and to assess the acquisition of additional chromosomal abnormalities (clonal evolution) in treatment-naïve del13q14 patients. A monoallelic deletion (del13qx1) was detected in 123 cases (88%), a biallelic deletion (del13qx2) in eight and a mosaic of monoallelic and biallelic deletions (del13qx1/del13qx2) in nine. In 33% of cases, deletion encompassed the Rb1 locus The median percentage of abnormal nuclei was 50% (15%-96%), and it was higher in patients with a biallelic/mosaic pattern in comparison with patients with monoallelic deletion. Sixty two patients (44%) have been treated; 5-year treatment free survival rate was 56% and the median treatment free survival was 65months. The baseline percentage of deleted nuclei, as a continuous variable, was related to progression (HR: 1.02; p=0.001). According to deletion burden, three groups were identified: 64 cases (46%) had

AB - This study analyzed 140 patients with isolated del13q14 on interphase FISH (I-FISH), to identify subsets with a different progression risk and to assess the acquisition of additional chromosomal abnormalities (clonal evolution) in treatment-naïve del13q14 patients. A monoallelic deletion (del13qx1) was detected in 123 cases (88%), a biallelic deletion (del13qx2) in eight and a mosaic of monoallelic and biallelic deletions (del13qx1/del13qx2) in nine. In 33% of cases, deletion encompassed the Rb1 locus The median percentage of abnormal nuclei was 50% (15%-96%), and it was higher in patients with a biallelic/mosaic pattern in comparison with patients with monoallelic deletion. Sixty two patients (44%) have been treated; 5-year treatment free survival rate was 56% and the median treatment free survival was 65months. The baseline percentage of deleted nuclei, as a continuous variable, was related to progression (HR: 1.02; p=0.001). According to deletion burden, three groups were identified: 64 cases (46%) had

KW - Chronic lymphocytic leukemia

KW - Del13q14

KW - Interphase-FISH

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84887026368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887026368&partnerID=8YFLogxK

U2 - 10.1002/hon.2032

DO - 10.1002/hon.2032

M3 - Article

C2 - 23060227

AN - SCOPUS:84887026368

VL - 31

SP - 136

EP - 142

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -